Bernadette Connaughton Sells 2,000 Shares of Halozyme Therapeutics (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Bernadette Connaughton sold 2,000 shares of the company’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $70.25, for a total transaction of $140,500.00. Following the completion of the transaction, the director directly owned 40,123 shares of the company’s stock, valued at $2,818,640.75. This represents a 4.75% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Bernadette Connaughton also recently made the following trade(s):

• On Monday, December 1st, Bernadette Connaughton sold 829 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $71.60, for a total value of $59,356.40.
• On Monday, November 10th, Bernadette Connaughton sold 2,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $68.48, for a total value of $136,960.00.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO traded up $1.93 during mid-day trading on Tuesday, reaching $73.13. The company’s stock had a trading volume of 3,809,586 shares, compared to its average volume of 3,049,947. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.59 and a quick ratio of 1.37. Halozyme Therapeutics, Inc. has a 52 week low of $47.50 and a 52 week high of $79.50. The stock has a fifty day moving average of $67.63 and a two-hundred day moving average of $66.21. The firm has a market capitalization of $8.60 billion, a PE ratio of 15.40, a P/E/G ratio of 0.31 and a beta of 0.94.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.63 by $0.09. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.The company had revenue of $354.26 million for the quarter, compared to the consensus estimate of $339.18 million. During the same quarter last year, the company earned $1.27 EPS. The firm’s quarterly revenue was up 22.1% on a year-over-year basis. As a group, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Morgan Stanley cut their target price on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a research note on Monday, October 20th. Leerink Partners raised shares of Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 price objective for the company in a report on Tuesday, October 14th. Benchmark boosted their target price on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Citizens Jmp raised their price target on Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a report on Tuesday, November 4th. Finally, JPMorgan Chase & Co. lifted their price objective on Halozyme Therapeutics from $63.00 to $65.00 and gave the stock a “neutral” rating in a research note on Monday, October 27th. Seven analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Halozyme Therapeutics presently has an average rating of “Hold” and an average price target of $75.10.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in HALO. DLD Asset Management LP raised its position in Halozyme Therapeutics by 20.0% during the third quarter. DLD Asset Management LP now owns 30,000,000 shares of the biopharmaceutical company’s stock valued at $2,200,200,000 after purchasing an additional 5,000,000 shares during the period. Arrowstreet Capital Limited Partnership increased its position in shares of Halozyme Therapeutics by 29.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock valued at $241,337,000 after purchasing an additional 749,484 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Halozyme Therapeutics by 3.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,078,426 shares of the biopharmaceutical company’s stock valued at $152,431,000 after purchasing an additional 63,699 shares during the last quarter. Federated Hermes Inc. raised its holdings in Halozyme Therapeutics by 294.1% during the 3rd quarter. Federated Hermes Inc. now owns 1,450,704 shares of the biopharmaceutical company’s stock valued at $106,395,000 after buying an additional 1,082,638 shares during the period. Finally, LSV Asset Management lifted its position in Halozyme Therapeutics by 0.9% in the third quarter. LSV Asset Management now owns 1,266,027 shares of the biopharmaceutical company’s stock worth $92,850,000 after buying an additional 10,787 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.